In the news
Upcoming events
Previous events
SNO
Society for Immunotherapy of Cancer Annual Meeting
November 6 – 10, 2024
George R. Brown Convention Center
Houston, Texas
2024 SNO/ASCO CNS Metastases Conference
August 8 – 10, 2024
Sheraton Denver Downtown Hotel
Denver, CO
SSG (SUBCORTICAL SURGERY GROUP)
12th Annual Tumor Models Boston Summit
July 17 — 18, 2024
The Colonnade Boston Hotel
Boston, MA
BIO International Convention
Baptist MCI Precision Medicine
American Association for Cancer Research (AACR) Annual Meeting Booth #3020
April 5 – 10, 2024
San Diego Convention Center
San Diego, CA
Southern Neurosurgical Society
Seattle Science Foundation Brain Tumor Mgmt.
8th Annual Tumor Models San Francisco Summit
January 31 – February 1, 2024
Grand Hyatt at SFO
San Francisco, CA
Kiyatec to attend partnering forum at BIO International 2023
Booth #3043 - SCBIO Pavillion
June 5-8, 2023
Boston, MA
Kiyatec’s CEO and business development team will be joining South Carolina’s life sciences delegation (SCBIO) at BIO International this June 5th-8th. Kiyatec will be focused on forming strategic partnerships with global biopharmaceutical companies to help triage and advance the most efficacious preclinical assets to the clinic.
Kiyatec to attend and showcase new clinical booth at the American Society for Clinical Oncology (ASCO)
Booth #25090
June 2-6, 2023
Chicago, IL
Kiyatec’s clinical team will attend ASCO this June to further expand upon its clinical presence. Kiyatec will be discussing how the 3D Predict™ test uses spheroid technology and patients’ own live cells to determine therapeutic response to chemo agents.
Kiyatec to host the High-Grade Glioma (HGG) Functional Precision Medicine Webinar Series
Tuesday April 25th, 2023 - 3pm EST
For this first installment of a six webinar series, join Dr. Phillips and Dr. Litvack to hear how the experts are using live patient-specific tumor tissue to predict therapeutic response(s) in HGG patients before treatment initiation. HGG has an extremely poor prognosis leading to inevitable recurrence with limited biomarkers available to predict treatment responses. This interactive multidisciplinary cancer discussion will feature two real world clinical cases, presented by their treating physicians, with a discussion moderated by our panel of experts. There will be time for attendees to participate in Q&A. This Functional Precision Medicine Webinar Series is powered by OncoLens.
Kester A. Phillips. MD
Medical Director, Neuro-Oncology
Swedish Neuroscience Institute
Seattle, Washington
Zachary N. Litvack, MD
Co-Director, Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington
Kiyatec to present multiple posters and feature new preclinical offerings at the American Association for Cancer Research (AACR)
April 14th-19th , 2023
Orange County Convention Center - Orlando, FL
Kate Appleton, PhD
Director of R&D
Immuno-Oncology
Title: Preclinical testing of therapeutic biologics using patient-derived 3D spheroids.
Melissa Millard, PhD
Director of R&D
New Model Development
Title: Perfused patient-derived organic models with autologous immune cells for preclinical drug development.
Kiyatec to Co-sponsor the 7th Tumor Models Immuno-Oncology Summit
Track A, 11:30am
January 25th , 2023
Marines’ Memorial Club and Hotel
Kiyatec Chief Scientific Officer Tessa DesRochers, PhD will speak at the 7th Tumor Models Immuno-Oncology Summit in San Francisco on January 25th, 2023. Kiyatec will be presenting – “Analyzing the modelling of T-cell specific Immuno-Therapies Deep-Diving into model applications for NK cell based therapeutics.” Using ex vivo human tumor models which incorporate tumor cells, and autologous immune cells, Kiyatec will be demonstrating the utility of their models to test T-cell specific therapies, including checkpoint inhibitors, bispecifics, and cellular therapies.
Kiyatec to present T-cell Reinvigoration & Persistence at Society for Immunotherapy of Cancer (SITC) 2022
Poster #162
Booth #447
November 8-12, 2022
Boston Convention & Exhibit Center
Kiyatec’s Senior Research Scientist, Katy Lassahn, MSc will present new insights at SITC 2022 in Boston: “Detecting T-cell Reinvigoration and Persistence Using Patient-derived ex vivo 3-dimensional spheroid models” featuring our tissue-agnostic ex vivo three-dimensional platform which recapitulates the tumor microenvironment for the assessment of T-cell performance — allows for testing of patient-specific T-cell reinvigoration and assessment of cell therapy product candidates in a cost-effective manner to expedite the preclinical product development process.
July 20 is #Glioblastoma Awareness Day
Kiyatec 3D Predict™ Glioma provides physicians with patient-specific predictive therapeutic response insights – before treatment begins.
Kiyatec to present spheroid technology at the 3D Tissue Summit in Boston, MA
Main Ballroom
July 13th, 2022
Hilton Boston Back Bay
Kiyatec Chief Scientific Officer Tessa DesRochers, PhD presents new R&D offerings to biopharma.
